PSI Opens New Italian Office
Today, PSI CRO, a full-service contract research organization, announced opening of a new operational office in Italy.
Today, PSI CRO, a full-service contract research organization, announced opening of a new operational office in Italy. The Italian office further expands PSI’s well-established presence in Europe and strengthens PSI’s ability to deliver global clinical trials. The PSI CRO Italy S.r.l. office is located just outside Milan at Via Badia n.55, 20060 Gessate. It will give PSI the location and support to continue attracting and recruiting top talent in the industry.
PSI has been placing clinical trials in Italy for a number of years on behalf of pharmaceutical and biotech sponsors. They have gained extensive knowledge and experience with local investigative sites in the areas of oncology, haematology, haemophilia, acute care, infectious diseases, CNS, diabetes, and other therapeutic areas.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
